• 1
    Fuchs HA, Sergent JS. Rheumatoid arthritis: the clinical picture. In: Koopman WJ, editor. Arthritis and allied conditions: a textbook of rheumatology. Baltimore: Williams & Wilkins; 1997. p. 104170.
  • 2
    Callahan LF, Cordray DS, Wells G, Pincus T. Formal education and five-year mortality in rheumatoid arthritis: mediation by helplessness scale score. Arthritis Care Res 1996; 9: 46372.
  • 3
    Kvalvik AG, Jones MA, Symmons DPM. Mortality in a cohort of Norwegian patients with rheumatoid arthritis followed from 1977 to 1992. Scand J Rheumatol 2000; 29: 2937.
  • 4
    Gabriel SE, Crowson CS, O'Fallon WM. Mortality in rheumatoid arthritis: have we made an impact in 4 decades? J Rheumatol 1999; 26: 252933.
  • 5
    Van der Heide A, Jacobs JWG, Bijlsma JWJ, Heurkens AHM, van Booma-Frankfort C, van der Veen MJ, et al. The effectiveness of early treatment with “second-line” antirheumatic drugs: a randomized, controlled trial. Ann Intern Med 1996; 124: 699707.
  • 6
    Quinn MA, Conaghan PG, Emery P. The therapeutic approach of early intervention for rheumatoid arthritis: what is the evidence? Rheumatology (Oxford) 2001; 40: 121120.
  • 7
    Symmons DPM, Jones MA, Scott DL, Prior P. Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. J Rheumatol 1998; 25: 10727.
  • 8
    Kraan MC, Versendaal H, Jonker M, Bresnihan B, Post WJ, 't Hart BA, et al. Asymptomatic synovitis precedes clinically manifest arthritis. Arthritis Rheum 1998; 41: 14818.
  • 9
    Conaghan PG, Wakefield RJ, O'Connor P, Gibbon WW, Brown C, McGonagle D, et al. MCPJ assessment in early RA: a comparison between x-ray, MRI, high-resolution ultrasound and clinical examination [abstract]. Arthritis Rheum 1998; 41 Suppl 9: S246.
  • 10
    Rantapää-Dahlqvist S, de Jong BAW, Berglin E, Hallmans G, Wadell G, Stenlund H, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003; 48: 27419.
  • 11
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 31524.
  • 12
    Aho K, Palusuo T, Kurki P. Marker antibodies of rheumatoid arthritis: diagnostic and pathogenetic implications. Semin Arthritis Rheum 1994; 23: 37987.
  • 13
    Nienhuis RLF, Mandema E. A new serum factor in patients with rheumatoid arthritis, the antiperinuclear factor. Ann Rheum Dis 1964; 23: 3025.
  • 14
    Young BJJ, Mallya RK, Leslie RDG, Clark CJM, Hamblin TJ. Anti-keratin antibodies in rheumatoid arthritis. Br Med J 1979; 2: 979.
  • 15
    Kurki P, Aho K, Palosuo T, Heliövaara M. Immunopathology of rheumatoid arthritis: antikeratin antibodies precede the clinical disease. Arthritis Rheum 1992; 35: 9147.
  • 16
    Van Boekel MAM, Vossenaar ER, van den Hoogen FHJ, van Venrooij WJ. Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arthritis Res 2002; 4: 8793.
  • 17
    Simon M, Girbal E, Sebbag M, Gomès-Daudrix V, Vincent C, Salama G, et al. The cytokeratin filament-aggregating protein filaggrin is the target of the so-called “antikeratin antibodies,” autoantibodies specific for rheumatoid arthritis. J Clin Invest 1993; 92: 138793.
  • 18
    Girbal E, Sebbag M, Gomès-Daudrix V, Simon M, Vincent C, Serre G. Characterisation of the rat oesophagus epithelium antigens defined by the so-called ‘antikeratin antibodies’, specific for rheumatoid arthritis. Ann Rheum Dis 1993; 52: 74957.
  • 19
    Sebbag M, Simon M, Vincent C, Masson-Bessière C, Girbal E, Durieux JJ, et al. The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J Clin Invest 1995; 95: 26729.
  • 20
    Schellekens GA, de Jong BAW, van den Hoogen FHJ, van de Putte LBA, van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998; 101: 27381.
  • 21
    Girbal-Neuhauser E, Durieux JJ, Arnaud M, Dalbon P, Sebbag M, Vincent C, et al. The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues. J Immunol 1999; 162: 58594.
  • 22
    Masson-Bessière C, Sebbag M, Durieux JJ, Nogueira L, Vincent E, Girbal-Neuhauser, Durroux R, et al. In the rheumatoid pannus, antifilaggrin autoantibodies are produced by local plasma cells and constitute a higher proportion of IgG than in synovial fluid and serum. Clin Exp Immunol 2000; 119: 54452.
  • 23
    Masson-Bessière C, Sebbag M, Girbal-Neuhauser E, Nogueira L, Vincent C, Senshu T, et al. The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the α- and β-chains of fibrin. J Immunol 2001; 166: 417784.
  • 24
    Van Venrooij WJ, Pruijn GJM. Citrullination: a small change for a protein with great consequences for rheumatoid arthritis. Arthritis Res 2000; 2: 24951.
  • 25
    Paimela L, Palosuo T, Aho K, Lukka M, Kurki P, Leirisalo-Repo M, et al. Association of autoantibodies to filaggrin with an active disease in early rheumatoid arthritis. Ann Rheum Dis 2000; 60: 325.
  • 26
    Schellekens GA, Visser H, de Jong BAW, van den Hoogen FHJ, Hazes JMW, Breedveld FC, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000; 43: 15563.
  • 27
    Shmerling RH, Delbanco TL. The rheumatoid factor: an analysis of clinical utility. Am J Med 1991; 91: 52834.
  • 28
    Meyer O, Combe B, Elias A, Benali K, Clot J, Sany J, et al. Autoantibodies predicting the outcome of rheumatoid arthritis: evaluation in two subsets of patients according to severity of radiographic damage. Ann Rheum Dis 1997; 56: 6825.
  • 29
    Munoz-Fernandez S, Avarez-Doforno R, Gonzalez-Tarrio JM, Balsa A, Richi P, Rontan G, et al. Antiperinuclear factor as a prognostic marker in rheumatoid arthritis. J Rheumatol 1999; 26: 25727.
  • 30
    Aho K, von Essen R, Kurki P, Palosuo T, Heliövaara M. Antikeratin antibody and antiperinuclear factor as markers for subclinical rheumatoid disease process. J Rheumatol 1993; 20: 127881.
  • 31
    Aho K, Palosuo T, Heliövaara M, Knekt P, Alha P, von Essen R. Antifilaggrin antibodies within “normal” range predict rheumatoid arthritis in a linear fashion. J Rheumatol 2000; 27: 27436.
  • 32
    Leslie D, Lipsky P, Notkins AL. Autoantibodies as predictors of disease. J Clin Invest 2001; 108: 141722.
  • 33
    Gottlieb PA, Eisenbarth GS. Diagnosis and treatment of pre-insulin dependent diabetes. Annu Rev Med 1998; 49: 391405.
  • 34
    Gale EAM. Can we change the course of beta-cell destruction in type 1 diabetes? N Engl J Med 2002; 346: 17401.
  • 35
    Diabetes Prevention Trial—Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002; 346: 168591.
  • 36
    Gardner SG, Gale EAM, Williams AJK, Gillespie KM, Lawrence KE, Bottazzo GF, et al. Progression to diabetes in relatives with islet autoantibodies: is it inevitable? Diabetes Care 1999; 22: 204954.
  • 37
    Robles DT, Eisenbarth GS, Wang T, Erlich HA, Bugawan TL, Babu SR, et al. Identification of children with early onset and high incidence of anti-islet autoantibodies. Clin Immunol 2002; 102: 21724.
  • 38
    Keller RJ, Eisenbarth GS, Jackson RA. Insulin prophylaxis in individuals at high risk of type I diabetes. Lancet 1993; 341: 9278.
  • 39
    Ziegler AG, Bachmann W, Rabl W. Prophylactic insulin treatment in relatives at high risk for type 1 diabetes. Diabetes Metab Rev 1993; 9: 28993.
  • 40
    Füchtenbusch M, Rabl W, Grassl B, Bachmann W, Standl E, Ziegler AG. Delay of type I diabetes in high risk, first degree relatives by parenteral antigen administration: the Schwabing Insulin Prophylaxis Pilot Trial. Diabetologia 1998; 41: 53641.
  • 41
    Schatz DA, Bingley PJ. Update on major trials for the prevention of type 1 diabetes mellitus: the American Diabetes Prevention Trial (DPT-1) and the European Nicotinamide Diabetes Intervention Trial (ENDIT). J Pediatr Endocrinol Metab 2001; 14 Suppl 1: 61922.
  • 42
    Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002; 346: 16928.
  • 43
    Arbuckle MR, James JA, Kohlhase KF, Rubertone MV, Dennis GJ, Harley JB. Development of anti-dsDNA autoantibodies prior to clinical diagnosis of systemic lupus erythematosus. Scand J Immunol 2001; 54: 2119.
  • 44
    Nepom GT, Nepom BS. Prediction of susceptibility to rheumatoid arthritis by human leukocyte antigen genotyping. Rheum Dis Clin North Am 1992; 18: 78592.
  • 45
    Jawaheer D, Gregersen PK. Rheumatoid arthritis: the genetic components. Rheum Dis Clin North Am 2002; 28: 115.